BioXcel receives positive FDA preliminary comments ahead of pre-sNDA meeting

BioXcel Therapeutics, Inc.

Positive preliminary FDA meeting comments received August 14, 2025.
Pre-sNDA meeting scheduled for August 20, 2025 to align on sNDA submission format and content.
Company evaluating feedback and plans to provide update next week.

item 8.01

Source: SEC EDGAR

accession 0001104659-25-079042

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.